<DOC>
	<DOCNO>NCT00935480</DOCNO>
	<brief_summary>To determine efficacy add Isentress® , without Celsentri® , effective conventional antiretroviral therapy ( comprise least 2 reverse transcriptase inhibitor one boost protease inhibitor ) , residual HIV replication blood cell gut-associated lymphoid tissue reservoir ( reverse transcriptase inhibitor : RTIs , boost protease inhibitor : PI/r ) . To evaluate effect therapy intensification mean integrase inhibitor without CCR5 inhibitor treatment lymphoid reservoir patient chronically infected HIV-1 , successfully treat `` conventional triple therapy '' , measure : - residual plasma replication 0 50 copies/ml - intracellular HIV RNA level circulate lymphocyte ( PBMC ) lymphocytes gut-associated rectal lymphoid tissue ( RL ) . - proviral HIV DNA level PBMC RL .</brief_summary>
	<brief_title>IntensVIH : Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Male female patient , age 18 year HIV infection confirm Western Blot Karnofsky score &gt; 80 % Treatmentexperienced patient receive combined antiretroviral therapy include least 2 RTI 1 PI/r least 12 month plasma viral load &lt; 50 copies/ml least 6 month Stable firstline treatment ( , change make reason relate viral resistance ) 2 RTIs 1 PI/r Proper safety compliance ongoing combination ; Patient agree undergo 3 proctosigmoidoscopy examination 12month period ; Plasma HIV1 RNA &lt; 50 copies/ml inclusion ; Circulating CD4 &gt; 200/mm3 inclusion ; Isentress® Celsentri®naïve patient No contraindication use investigational product Written , inform consent , obtain patient his/her legal representative . 1 . Opportunistic infection active tumor disease 2 . Chronic diarrhea , malabsorption , progressive enteric infection 3 . Aged 18 year 4 . Pregnancy breastfeeding ( pregnancy test do inclusion visit ) 5 . Coinfection HIV2 6 . History immunomodulator treatment ( interleukin2 , alphainterferon ) 7 . Ongoing treatment HBV HCV coinfection 8 . Blood constitution disorder 9 . Contraindications administration raltegravir maraviroc 10 . Circulating CD4 nadir &lt; 100/mm3 natural history HIV1 infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>INTEGRASE INHIBITOR</keyword>
	<keyword>Inhibitor lymphoid reservoir</keyword>
	<keyword>Residual HIV replication</keyword>
	<keyword>treatment experience</keyword>
</DOC>